Innovating Works

FINOVATIS

Desconocido
MANCO: Monoclonal Antibodies against 2019 New Coronavirus FINOVATIS participó en un H2020: H2020-SC1-PHE-CORONAVIRUS-2020 "Lessons learned from, and intervention efforts against SARS coronavirus (CoV), MERS-CoV and other emerging viruses provide invaluable infor...
2020-04-07 - 2023-05-31 | Financiado
MCDS-Therapy: Repurposing of carbamazepine for treatment of skeletal dysplasia FINOVATIS participó en un H2020: H2020-SC1-2016-2017 Genetic skeletal diseases (GSDs) are an extremely diverse and complex group of rare genetic diseases that affect the development the skeleto...
2017-12-05 - 2024-05-31 | Financiado
CanPathPro: Generation of the CanPath prototype a platform for predictive cancer pathway modeling FINOVATIS participó en un H2020: H2020-BIOTEC-2014-2015 Recent developments in omics technologies demand implementation of systems biology approaches to facilitate analysis and interpretation of t...
2016-02-25 - 2021-11-30 | Financiado
ZAPI: Zoonotic Anticipation and Preparedness Initiative FINOVATIS participó en un FP6: Emerging infectious diseases are occurring at increasing frequency in Europe and other regions of the world, having profound impacts on publ...
2015-03-01 - 2020-02-29 | Financiado
RD-CONNECT: RD CONNECT An integrated platform connecting registries biobanks and clinical bioinformatics for r... FINOVATIS participó en un FP7: Despite examples of excellent practice, rare disease (RD) research is still mainly fragmented by data and disease types. Individual efforts...
Financiado
CELL-PID: Advanced Cell based Therapies for the treatment of Primary ImmunoDeficiency FINOVATIS participó en un FP7: Primary immune deficiencies (PID) are inherited disorders of the adaptive and innate immune system marked by severe infections, autoimmunity...
Financiado
ZAPI: Zoonotic Anticipation and Preparedness Initiative FINOVATIS participó en un FP7: Emerging infectious diseases are occurring at increasing frequency in Europe and other regions of the world, having profound impacts on publ...
Financiado
SYBIL: Systems biology for the functional validation of genetic determinants of skeletal diseases FINOVATIS participó en un FP7: "The aim of SYBIL is to carry out extensive functional validation of the genetic determinants of rare and common skeletal diseases and the a...
Financiado
NET4CGD: Gene Therapy for X linked Chronic Granulomatous Disease CGD FINOVATIS participó en un FP7: This project is focused on the clinical development of a new orphan drug that can rapidly become a new treatment option for patients with th...
Financiado
SYSCLAD: Systems prediction of Chronic Lung Allograft Dysfunction FINOVATIS participó en un FP7: Lung transplantation (LT) is the standard of care for selected patients with chronic respiratory failure. Chronic lung allograft dysfunctio...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.